Volitinib (Savolitinib), SAR125844, tepotinib (EMD1214063), capmatinib (INCB28060), AMG337, Indo5, tivantinib, and PHA665752 are of such selective c-Met inhibitors [156,157,158,159,160], which showed anti-tumor effects in various cancers with high MET expression, including gastric and hepatocellular carcinoma, papillary renal carcinoma, and NSCLC [158, 161]
zerumbet , have been evaluated for their immunomodulating effects, particularly via signaling pathways
Key exclusion criteria included diabetes, previous or planned surgical treatment for obesity, use of medications that promote weight loss or gain, or a weight change of more than 5 kg in the three months before screening
Additionally, in addition to targeting neuronal cells, targeting immunometabolic reprogramming in astrocytes to prevent neuroinflammation may present a new avenue for ND treatment, necessitating the differentiation of various cell types within the substance